Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.5038
+0.1115 (28.42%)
At close: Apr 1, 2025, 4:00 PM
0.4830
-0.0208 (-4.13%)
After-hours: Apr 1, 2025, 4:27 PM EDT
Equillium Revenue
In the year 2024, Equillium had annual revenue of $41.10M with 13.89% growth. Equillium had revenue of $4.39M in the quarter ending December 31, 2024, a decrease of -52.32%.
Revenue (ttm)
$41.10M
Revenue Growth
+13.89%
P/S Ratio
0.34
Revenue / Employee
$933,977
Employees
44
Market Cap
17.94M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
EQ News
- 5 days ago - Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients - Benzinga
- 5 days ago - Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Business Wire
- 5 days ago - Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - Business Wire
- 7 weeks ago - Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - Business Wire
- 4 months ago - Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - Business Wire
- 4 months ago - Equillium to Present at the Stifel Healthcare Conference - Business Wire
- 5 months ago - Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - Business Wire
- 5 months ago - Equillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire